跳轉至內容
Merck
全部照片(1)

文件

740500

Sigma-Aldrich

壳聚糖

high purity, Mv 110,000-150,000

同義詞:

KiOmedine-CsU® B, 聚（D-氨基葡萄糖）, 脱乙酰几丁质

登入查看組織和合約定價
全部照片(1)

About This Item

CAS號碼:
9012-76-4
MDL號碼:
MFCD00161512
分類程式碼代碼:
12352201

生物源

white mushroom

等級

high purity

形狀

powder

分子量

Mv 110,000-150,000

成份

Bacterial endotoxins, ≤10 EU/g
Beta-glucan, ≤5 % (w/w)
Chitosan, ≥93 % (w/w)
Proteins, ≤1 % (w/w)

黏度

5-200 mPa.s (1% solution in 1% HAc)

溶解度

acetic acid: 1% (solution)

儲存溫度

2-8°C

InChI

1S/C56H103N9O39/c1-87-56(86)65-28-38(84)46(19(10-74)96-55(28)104-45-18(9-73)95-49(27(64)37(45)83)97-39-12(3-67)88-47(85)20(57)31(39)77)103-54-26(63)36(82)44(17(8-72)94-54)102-53-25(62)35(81)43(16(7-71)93-53)101-52-24(61)34(80)42(15(6-70)92-52)100-51-23(60)33(79)41(14(5-69)91-51)99-50-22(59)32(78)40(13(4-68)90-50)98-48-21(58)30(76)29(75)11(2-66)89-48/h11-55,66-85H,2-10,57-64H2,1H3,(H,65,86)/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48+,49+,50+,51+,52+,53+,54+,55+/m1/s1

InChI 密鑰

FLASNYPZGWUPSU-SICDJOISSA-N

尋找類似的產品？ 前往 產品比較指南

一般說明

KiOmedine-CSU® is an ultra-pure chitosan of non-animal origin, produced from white mushrooms (Agaricus bisporus), in accordance with cGMP.
The crystalline structure is in the alpha form. The linkage between glucosamine units is beta(1,4).

應用

与多价阴离子形成凝胶。 产生透明溶液，干燥后形成坚固、透明的薄膜。
表面改性;组织工程和药物输送

特點和優勢

生物相容、抗菌和环保的聚电解质，其具有多种应用，包括水处理、色谱法、化妆品添加剂、抗微生物活性的纺织品处理、纺织品的新型纤维、照相纸、可生物降解的薄膜、生物医学装置、以及用于药物递送中控制释放的微胶囊植入物。

物理性質

乙酰化度: ≤40 mol. %

法律資訊

KitoZyme产品
KiOmedine is a registered trademark of KitoZyme, S.A.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

nwg

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Alberto Busilacchi et al.
Carbohydrate polymers, 98(1), 665-676 (2013-08-31)
The idea of using chitosan as a functional delivery aid to support simultaneously PRP, stem cells and growth factors (GF) is associated with the intention to use morphogenic biomaterials to modulate the natural healing sequence in bone and other tissues.
Stephanie Supper et al.
Expert opinion on drug delivery, 11(2), 249-267 (2013-12-07)
Thermogelling chitosan (CS)/glycerophosphate (GP) solutions have been reported as a new type of parenteral in situ forming depot system. These free-flowing solutions at ambient temperature turn into semi-solid hydrogels after parenteral administration. Formulation parameters such as CS physico-chemical characteristics, CS/gelling
Liming Hu et al.
Nanoscale, 5(8), 3103-3111 (2013-03-22)
Within the past few years, chitosan-based drug delivery vehicles have become some of the most attractive to be studied. In contrast to all other polysaccharides, chitosan has demonstrated its unique characteristics for drug delivery platforms, including its active primary amino
William D Stanish et al.
The Journal of bone and joint surgery. American volume, 95(18), 1640-1650 (2013-09-21)
Microfracture, the standard of care, is recognized to be an incomplete solution for cartilage damage. BST-CarGel, a chitosan-based medical device, is mixed with autologous whole blood and is applied to a microfractured cartilage lesion in which it physically stabilizes the
Electrochemical biosensor applications of polysaccharides chitin and chitosan.
Wipa Suginta et al.
Chemical reviews, 113(7), 5458-5479 (2013-04-06)
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務